[go: up one dir, main page]

BR9916759A - Processo para tratamento de distúrbios sexuais - Google Patents

Processo para tratamento de distúrbios sexuais

Info

Publication number
BR9916759A
BR9916759A BR9916759-0A BR9916759A BR9916759A BR 9916759 A BR9916759 A BR 9916759A BR 9916759 A BR9916759 A BR 9916759A BR 9916759 A BR9916759 A BR 9916759A
Authority
BR
Brazil
Prior art keywords
sexual disorders
treating sexual
dose
sexually
mating
Prior art date
Application number
BR9916759-0A
Other languages
English (en)
Inventor
Martin Durham Meglasson
Robert B Mccall
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9916759A publication Critical patent/BR9916759A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<B>PROCESSO PARA TRATAMENTO DE DISTúRBIOS SEXUAIS<D> A presente invenção se refere a um processo para tratamento de distúrbios sexuais em seres humanos e indução de acasalamento em mamíferos não humanos usando os compostos da fórmula (A) em uma faixa de dosagem onde a quantidade sexualmente terapêutica é de cerca de 0,2 a cerca de 8 mg/pessoa/dose e onde a quantidade sexualmente usada para acasalamento é de cerca de 0,003 a cerca de 0,2 mg/kg/dose.
BR9916759-0A 1999-01-06 1999-12-20 Processo para tratamento de distúrbios sexuais BR9916759A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11484099P 1999-01-06 1999-01-06
US11505199P 1999-01-08 1999-01-08
US11592299P 1999-01-14 1999-01-14
US12054399P 1999-02-17 1999-02-17
PCT/US1999/027951 WO2000040226A2 (en) 1999-01-06 1999-12-20 Method of treating sexual disturbances

Publications (1)

Publication Number Publication Date
BR9916759A true BR9916759A (pt) 2001-09-25

Family

ID=27493976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916759-0A BR9916759A (pt) 1999-01-06 1999-12-20 Processo para tratamento de distúrbios sexuais

Country Status (20)

Country Link
US (9) US6455564B1 (pt)
EP (1) EP1140092A2 (pt)
JP (1) JP2002534376A (pt)
KR (1) KR20010089779A (pt)
CN (1) CN1332628A (pt)
AU (1) AU782596B2 (pt)
BR (1) BR9916759A (pt)
CA (1) CA2350946A1 (pt)
CO (1) CO5150156A1 (pt)
CZ (1) CZ20012459A3 (pt)
EA (2) EA005412B1 (pt)
HK (1) HK1041812A1 (pt)
HU (1) HUP0105036A3 (pt)
ID (1) ID30276A (pt)
IL (1) IL144172A0 (pt)
NZ (1) NZ512820A (pt)
PE (1) PE20001374A1 (pt)
SK (1) SK7732001A3 (pt)
TR (1) TR200101895T2 (pt)
WO (1) WO2000040226A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
PL349912A1 (en) * 1999-02-05 2002-10-07 Upjohn Co Process to prepare (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one
EP1175204A4 (en) * 1999-05-04 2006-05-31 Aradigm Corp AEROSOL FORMULATION AND ARTICLES FOR INCREASING LIBIDO IN WOMEN BY MOMENTARY TESTOSTERONE ADMINISTRATION
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
WO2001000221A2 (en) * 1999-06-23 2001-01-04 Institut Pasteur Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
CA2405565A1 (en) 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
WO2002062315A1 (en) * 2001-02-08 2002-08-15 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
US20030073609A1 (en) 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
CA2500919A1 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
EP1546120A4 (en) * 2002-10-04 2006-11-22 Pharmacia Corp PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
CA2536874A1 (en) * 2003-09-05 2005-03-17 Novartis Ag Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
BRPI0615972A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
US7615075B2 (en) * 2005-11-04 2009-11-10 Rush University Medical Center Plastic implant impregnated with a degradation protector
US20080004310A1 (en) * 2006-06-19 2008-01-03 Applied Pharmacy Services, Inc. Lyophilized pharmaceutical composition
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders
TWI795440B (zh) 2017-09-15 2023-03-11 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
BR112020026783A2 (pt) 2018-06-29 2021-03-30 Forma Therapeutics, Inc. Inibição da proteína de ligação creb (cbp)
BR112021016921A2 (pt) * 2019-03-15 2021-11-03 Forma Therapeutics Inc Inibição de proteína de ligação a elemento responsivo a amp cíclico (creb)
EP3937940A4 (en) 2019-03-15 2022-12-21 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
EP4039746A1 (de) 2021-02-08 2022-08-10 Covestro Deutschland AG Polycarbonat-polyester zusammensetzung, formmasse und formkörper mit guter schlagzähigkeit und hoher thermischer belastbarkeit

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4935514A (en) * 1989-06-06 1990-06-19 Ethyl Corporation Thiation process
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5541211A (en) 1991-06-18 1996-07-30 Orion-Yhtyma Oy Administration of atipamezole to elicit a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic transmission
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
KR100335548B1 (ko) * 1993-07-27 2002-10-04 파마시아 앤드 업존 캄파니 중추신경계활성을갖는헤테로사이클아민
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE10199068I2 (de) 1994-04-22 2004-05-06 Pentech Pharmaceuticals Inc Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
CA2256889A1 (en) * 1996-05-31 1997-12-04 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives having cgmp-pde inhibitory effect
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances

Also Published As

Publication number Publication date
CN1332628A (zh) 2002-01-23
CZ20012459A3 (cs) 2002-01-16
AU782596B2 (en) 2005-08-11
EA200100750A1 (ru) 2001-12-24
AU2348200A (en) 2000-07-24
HK1041812A1 (zh) 2002-07-26
ID30276A (id) 2001-11-15
SK7732001A3 (en) 2001-12-03
EP1140092A2 (en) 2001-10-10
HUP0105036A2 (hu) 2002-05-29
US6890945B2 (en) 2005-05-10
EA005412B1 (ru) 2005-02-24
KR20010089779A (ko) 2001-10-08
US6903127B2 (en) 2005-06-07
US20030013710A1 (en) 2003-01-16
US20040214824A1 (en) 2004-10-28
US6921771B2 (en) 2005-07-26
WO2000040226A2 (en) 2000-07-13
NZ512820A (en) 2002-12-20
CA2350946A1 (en) 2000-07-13
US20040214823A1 (en) 2004-10-28
JP2002534376A (ja) 2002-10-15
CO5150156A1 (es) 2002-04-29
US6455564B1 (en) 2002-09-24
TR200101895T2 (tr) 2001-12-21
US20040214826A1 (en) 2004-10-28
IL144172A0 (en) 2002-05-23
US20030004152A1 (en) 2003-01-02
PE20001374A1 (es) 2000-11-19
US20040214825A1 (en) 2004-10-28
EA200401256A1 (ru) 2005-12-29
US6809112B2 (en) 2004-10-26
US20020198187A1 (en) 2002-12-26
US20020107247A1 (en) 2002-08-08
WO2000040226A3 (en) 2001-02-01
HUP0105036A3 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
BR9916759A (pt) Processo para tratamento de distúrbios sexuais
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
UY26130A1 (es) Compuestos para tratar la obesidad
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
MXPA04004966A (es) Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
BR9306042A (pt) Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
BRPI0410927A (pt) métodos terapêuticos e profiláticos para distúrbios neuromusculares
BRPI0011867B8 (pt) preparação farmacêutica de levodopa/carbidopa/entacapona e processo para preparação da mesma
NZ514574A (en) Novel method of treatment
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
BR0005276A (pt) Compostos para o tratamento de disfução sexual feminina
BG104727A (en) Pharmaceutical composition of topiramate
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
ATE282418T1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
EP0957925A4 (en) TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE
KR970061244A (ko) 치매 치료용 약학 조성물
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA(S) 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009.